📊 CTOR Key Takeaways
Investment Thesis
Citius Oncology is a pre-commercial stage pharmaceutical company with minimal revenue generation ($3.9M) and substantial operating losses (-$5.3M). The company is burning cash at an unsustainable rate (-$7.4M operating cash flow) with only $7.3M in cash reserves, creating severe liquidity concerns. Without meaningful revenue growth or a clear path to profitability, the company faces existential funding risks.
CTOR Strengths
- High gross margin (80%) on limited revenue suggests strong pricing power if commercialization succeeds
- Positive stockholders' equity ($58.4M) provides some balance sheet cushion
- Low debt burden (0.00x Debt/Equity) avoids near-term refinancing pressure
CTOR Risks
- Critical liquidity crisis: current ratio of 0.83x and quick ratio of 0.32x indicate inability to cover near-term obligations
- Severe cash burn rate: -$7.4M operating cash flow with only $7.3M cash equivalents implies less than 1 year of runway at current burn rate
- No revenue growth trajectory: $3.9M annual revenue is insufficient to support R&D operations; company is entirely dependent on capital infusion
- Negative profitability across all metrics with -140.3% net margin and -186.5% free cash flow margin
- Early-stage pharma with no demonstrated commercial success or pipeline visibility in available data
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Clinical trial progress and regulatory milestones for pipeline assets
- Revenue growth rate and customer acquisition from commercialization efforts
- Future capital raise announcements and dilution impact
- Operating cash flow trajectory and path to cash flow breakeven
CTOR Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CTOR Profitability Ratios
CTOR vs Healthcare Sector
How CITIUS ONCOLOGY, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTOR Balance Sheet & Liquidity
CTOR 5-Year Financial Trend
5-Year Trend Summary: CITIUS ONCOLOGY, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.31 indicates the company is currently unprofitable.
CTOR Growth Metrics (YoY)
CTOR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.9M | -$5.5M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CTOR Capital Allocation
CTOR SEC Filings
Access official SEC EDGAR filings for CITIUS ONCOLOGY, INC. (CIK: 0001851484)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTOR
What is the AI rating for CTOR?
CITIUS ONCOLOGY, INC. (CTOR) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTOR's key strengths?
High gross margin (80%) on limited revenue suggests strong pricing power if commercialization succeeds. Positive stockholders' equity ($58.4M) provides some balance sheet cushion.
What are the risks of investing in CTOR?
Critical liquidity crisis: current ratio of 0.83x and quick ratio of 0.32x indicate inability to cover near-term obligations. Severe cash burn rate: -$7.4M operating cash flow with only $7.3M cash equivalents implies less than 1 year of runway at current burn rate.
What is CTOR's revenue and growth?
CITIUS ONCOLOGY, INC. reported revenue of $3.9M.
Does CTOR pay dividends?
CITIUS ONCOLOGY, INC. does not currently pay dividends.
Where can I find CTOR SEC filings?
Official SEC filings for CITIUS ONCOLOGY, INC. (CIK: 0001851484) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTOR's EPS?
CITIUS ONCOLOGY, INC. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.